Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors. - Wikidata - wikimedia - TriplyDB

Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors.

Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors.

http://www.wikidata.org/entity/Q43262499

about

Modeling the effects of β1-adrenergic receptor blockers and polymorphisms on cardiac myocyte Ca2+ handling.Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol Beta1-adrenoceptor polymorphism predicts flecainide action in patients with atrial fibrillation.RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications Human atrial β(1L)-adrenoceptor but not β₃-adrenoceptor activation increases force and Ca(2+) current at physiological temperature.The genomic architecture of sporadic heart failure Overexpression of beta 1-adrenoceptors in adult rat ventricular myocytes enhances CGP 12177A cardiostimulation: implications for 'putative' beta 4-adrenoceptor pharmacology Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.Beta1- and beta2-adrenoceptor polymorphisms and cardiovascular diseases.Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure Pharmacogenetic profiling in the treatment of heart disease.Pharmacogenomics of beta-adrenergic receptors and their accessory signaling proteins in heart failure.Adrenergic signaling polymorphisms and their impact on cardiovascular disease.Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human β1-adrenoceptor expressed in HEK-293 cells.Negative cooperativity across β1-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor binding conformation.Interhelical interaction and receptor phosphorylation regulate the activation kinetics of different human β1-adrenoceptor variants.Functional effects of β₁-adrenoceptor polymorphisms on the hemodynamic response to dobutamine with and without β-blocker administration.β1-adrenoceptor gene Arg389Gly polymorphism and essential hypertension risk in general population: a meta-analysis.

P2860

Q30371695-CAA15C01-5B38-4B63-A75D-97DA0CFA821B Q30478644-846DF905-DF05-4FEA-9009-0BDEF4F78C36 Q33631107-E40E528F-EB4A-4BF1-81A5-CA725FA165C1 Q34390058-FF9878FA-251D-4FB9-ABCD-8942D8FD69A8 Q34588659-29F8FB5E-F8F7-479B-8FF7-2E6BD5EC6B57 Q35033305-0AFE9F55-3AC7-4CA7-BC25-D23502E5BD40 Q35046211-56F7A6CF-80C4-44DD-8D18-FA800BE512A1 Q35046547-D6E7E46A-DE04-4218-B56E-2BB199265659 Q37033656-C6118DCD-1305-41EB-B53F-C166970B08CC Q37114101-D7490842-38A3-4826-A060-3DC6A8BAA655 Q37314365-38A3B5A8-2469-4252-B73C-341F3D85202A Q37636713-37D69C20-FF11-4F19-AD9B-5A61F303288C Q37742683-6B37B2A9-8817-4BE5-8C8C-0A31AA7CBE20 Q37776088-1E423776-5BFF-437C-817B-9290A546378A Q38738498-6C11FF13-DD48-4457-BCFA-B16EE44D357C Q39428983-4C722970-332D-478D-9B89-994776A53D1C Q42149596-2AC896D0-8B6A-4872-B185-73180ABE1B74 Q42556942-BBB099D0-F36D-46F6-A1D8-554027F14651 Q42915812-6438EA09-D9AF-4686-BC35-AD6E1498E0B0 Q51066810-A28C13C8-8EE4-435B-A258-337528F3CFE1

P2860

Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors.

http://www.wikidata.org/entity/Q43262499

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Markedly reduced effects of (- ...... to Arg389-beta1-adrenoceptors.

@en

Markedly reduced effects of

@nl

type

label

Markedly reduced effects of (- ...... to Arg389-beta1-adrenoceptors.

@en

Markedly reduced effects of

@nl

prefLabel

Markedly reduced effects of (- ...... to Arg389-beta1-adrenoceptors.

@en

Markedly reduced effects of

@nl

P1433

Q43262499-DF74283D-BAC7-4CF0-B802-41CD0BCA9DA5

P1476

Q43262499-F0E69B97-DAAF-4F66-B73E-F721B5300235

P2093

Q43262499-035372FC-C413-436A-8EC0-55653B8E4EFD

Q43262499-33069AC5-9FE1-4328-837C-A3049DDCB252

Q43262499-830A6E3A-CF8E-4ADC-99E1-3C6624A01019

Q43262499-852F737B-3C16-41B5-A9D9-A5EA2C1CDFE9

P2860

Q43262499-04E08433-96E1-48A5-9E78-AF3B89FF5197

Q43262499-0DB21AC2-BB23-44C8-9F32-F8EA00CD81B7

Q43262499-1CF81236-1DEB-406B-90F7-B9E55A1A9EDA

Q43262499-21702CA4-1CE6-49E5-8761-96243F5198F2

Q43262499-2B657F7E-E9AD-4D2B-96FA-54E53175B496

Q43262499-4161B92D-85BB-4BE2-9F7D-E4093861D57A

Q43262499-43CCF170-5600-4570-82DA-B475831B4A89

Q43262499-4560CE00-A4D6-41B9-AFB0-96BD7BB9A587

Q43262499-48EFB13A-2B24-4C65-8641-87228DE72938

Q43262499-4F33A36A-797E-478E-BB64-87E1F74D28F4

P304

Q43262499-0369B70E-E6CE-4D7E-8C6D-892AA710E2BA

P31

Q43262499-F6195D3A-BE76-4B33-8F41-892FA3561866

P356

Q43262499-687673D0-D99C-4207-8417-47F98504C5A1

P407

Q43262499-59956927-1FAC-4560-9706-AAEAD0791308

P433

Q43262499-29F2E4A8-7DB1-4325-8F86-4ECFBC475B29

P478

Q43262499-C07843D4-070E-4B47-8886-D156873FFCD7

P50

Q43262499-64E952DC-B6EE-4809-BB73-DADC8EEBC376

P577

Q43262499-60E1F730-9644-4BCF-B11B-9C499834D1A1

P5875

Q43262499-0E10B11F-9283-4343-AED7-C8FDD7B7F3DA

P698

Q43262499-C75CF482-52AD-4227-8B7A-AF1F355F23CD

P932

Q43262499-F330998B-8395-4445-B2E8-1062653D5144

P356

P1433

British Journal of Pharmacology

P1476

Markedly reduced effects of (- ...... to Arg389-beta1-adrenoceptors

@en

P2093

A A Grace

http://www.w3.org/2001/XMLSchema#string

A J Kaumann

http://www.w3.org/2001/XMLSchema#string

J A Lynham

http://www.w3.org/2001/XMLSchema#string

S S Joseph

http://www.w3.org/2001/XMLSchema#string

P2860

A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor

Tight control of gene expression in mammalian cells by tetracycline-responsive promoters

Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors

In-vivo studies do not support a major functional role for the Gly389Arg beta 1-adrenoceptor polymorphism in humans.

The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor.

Putative beta 4-adrenoceptors in rat ventricle mediate increases in contractile force and cell Ca2+: comparison with atrial receptors and relationship to (-)-[3H]-CGP 12177 binding.

Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 beta 1-adrenoceptors versus Gly389 beta 1-adrenoceptors in isolated human atrial myocardium

Pharmacology and physiology of human adrenergic receptor polymorphisms.

(-)-CGP 12177-induced increase of human atrial contraction through a putative third beta-adrenoceptor

Is there a third heart beta-adrenoceptor?

P304

51-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0705753

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

142

http://www.w3.org/2001/XMLSchema#string

P50

William H. Colledge

P577

2004-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8662264

http://www.w3.org/2001/XMLSchema#string

P698

15037517

http://www.w3.org/2001/XMLSchema#string

P932

1574932

http://www.w3.org/2001/XMLSchema#string